newsfilter
← Latest News
Business Wire·

Monsanto Announces Global Genome-Editing Licensing Agreement With Broad Institute For Newly-Characterized CRISPR System

ST. LOUIS--(BUSINESS WIRE)--Monsanto Company (NYSE: MON) announced today that it has reached a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPR-Cpf1 genome-editing technology in agriculture. The CRISPR-Cpf1 system represents an exciting advance in genome-editing technology, because it has potential to be a simpler and more precise tool for making targeted improvements in a cell's DNA when compared to the CRISPR-Cas9 system.